BioSpace News Archive

Axena Health, Inc. (Axena Health), a medical device company focused on female pelvic health, announced today that leading pelvic health researchers have published a new study demonstrating the Leva® Pelvic Health System’s long-term treatment efficacy for female urinary incontinence (UI).

Unnatural Products, Inc. (UNP) today announced a collaboration withMerck, known as MSD outside the United States and Canada, to apply UNP’s technology to design and develop macrocyclic candidates against an oncology therapeutic target.

Mercury Bio today announced that it has joined the Alliance for mRNA Medicines as a charter member, and that Chief Science Officer Richard Sayre, Ph.D. has joined the Alliance for mRNA Medicines (AMM) board.

Taiho Oncology, Inc. announces publication of the final results from the pivotal ASCERTAIN clinical trial of fixed-dose oral decitabine and cedazuridine (INQOVI®) compared to intravenous decitabine in adults with intermediate and high-risk myelodysplastic syndromes (MDS) including chronic myelomonocytic leukemia (CMML).

Aytu BioPharma, Inc. today announced that Josh Disbrow, CEO, will participate in a fireside chat and host one-on-one meetings with investors at the Lytham Partners 2024 Investor Select Conference taking place virtually on February 1, 2024.

BostonGene today announced a master agreement with Duke University School of Medicine to collaborate on multiple research projects across lung cancer, gastrointestinal, genitourinary and skin cancers.

City of Hope announced the appointment of Kristin Higgins, M.D., as the chief clinical officer at City of Hope Cancer Center Atlanta.

AtlasXomics and EpiCypher announce their partnership to develop CUT&Tag kits and assay services for spatial epigenomics applications.

IDBS announced that it has entered into a partnership with Massachusetts-based PharmaEssentia Innovation Research Center on its Polar platform to help digitize data management and facilitate collaboration between the company’s global research and development teams.

Sight Sciences, Inc., an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients’ lives, announced the closing of an up to $65 million senior secured credit facility with Hercules Capital, Inc., a leader in customized debt financing for companies in life sciences and technology-related markets.